Peptide Nomenclature and Directionality
Read the sentence "Ala-Gly-Lys" and you have already made a decision. You may not have noticed it. You have agreed that alanine comes first, glycine second, lysine third. You have also agreed that "first" means something chemically specific. That convention is not arbitrary bookkeeping. It encodes the direction in which every ribosome on Earth actually builds a protein. It also fixes, uniquely, which end of the molecule carries a free α-amino group. It likewise fixes which end carries a free α-carboxylate. Get the direction backward and "Ala-Gly-Lys" becomes a different molecule. It will have different charge, different shape, and potentially zero biological activity. Lys-Gly-Ala is not a typo of Ala-Gly-Lys. It is a structural isomer. This matters because peptide and protein sequences are the primary data of molecular biology. Every gene database entry is a string of codes read in a fixed direction. So is every mass-spectrometry search and every synthesis order to a peptide-synthesis company. These use one-letter or three-letter codes read in a fixed direction. A single reversed sequence submitted to a peptide synthesizer produces the wrong molecule. This happens at real cost. Synthetic peptides are priced per residue. A mirrored sequence is simply not the compound the biologist wanted. Understanding why the convention is N-to-C, not C-to-N or arbitrary, requires effort. It requires connecting the chemistry of The Peptide Bond and Its Formation to the machinery of ribosomal synthesis. Understanding the naming rules requires something else. It requires walking through exactly how IUPAC constructs a peptide's name from its constituent amino acids. The big picture is this: a peptide is a linear polymer with a built-in, chemically enforced polarity. This is exactly like a piece of one-way rope with two structurally distinct ends. One end retains a free, protonatable α-amino group (the N-terminus). The other retains a free, deprotonatable α-carboxyl group (the C-terminus). Peptide bond formation always joins the carboxyl of one residue to the amino group of the next. Ribosomes always extend a chain by adding new residues to the growing C-terminus. Because of this, sequence, numbering, and naming all inherit a single, non-negotiable direction. N-terminus first, C-terminus last. This article works through the logic of that convention from first principles. It explains why the peptide bond forces directionality. It shows how residue numbering and the one- and three-letter alphabets are constructed. It shows how to build an unambiguous IUPAC name for a short peptide. It also shows how sequence orientation surfaces later in Chemical Synthesis of Peptides and Peptide Sequencing Strategies. By the end you should be able to write, read, and number any peptide sequence without hesitation. You should also be able to explain precisely why "reversing" a peptide is chemically consequential rather than cosmetic.
- A peptide has two chemically distinct ends: the N-terminus (free α-NH₃⁺) and the C-terminus (free α-COO⁻); this asymmetry is called directionality.
- By universal convention, peptide sequences are written, numbered, and synthesized from N-terminus (residue 1) to C-terminus (residue n).
- Each amino acid contributes a three-letter code (e.g., Ala, Gly, Lys) and a one-letter code (A, G, K); both are read left-to-right as N→C.
- IUPAC peptide names are built by naming each residue except the last as an "-yl" acyl substituent, ending in the unmodified C-terminal amino acid name.
- Residue numbering follows chain position from the N-terminus and is used to specify mutations (e.g., Gly12Val) and active-site residues unambiguously.
- Ribosomes synthesize proteins exclusively N-to-C, so biological directionality and nomenclature directionality are the same physical direction.
- Key idea: peptide bond formation consumes one residue's carboxyl and another's amino group, so a chain of n residues has exactly one free amino terminus and one free carboxyl terminus — and by convention we always read, number, and name that chain starting from the amino end.
Where this lives today
Every peptide sequence you will encounter in modern biochemistry — in UniProt entries, PDB structure files, mass spectrometry search databases (like Mascot or MaxQuant), CRISPR-edited protein variant annotations, and pharmaceutical peptide drug patents — is written N-to-C by unbreakable convention, and this convention is load-bearing infrastructure, not decoration. Clinical genetics reports variant nomenclature such as "p.Gly12Val" (as in the classic KRAS G12V oncogenic mutation found in many cancers) using exactly the N→C residue-numbering convention developed here; misreading the direction would misidentify which residue is mutated in a patient's tumor sequencing report. In peptide drug synthesis (solid-phase peptide synthesis, the technology behind Chemical Synthesis of Peptides), the chain is actually built C-to-N on the solid support — the first amino acid is anchored to resin through its carboxyl group, and subsequent residues are added by activating each new amino acid's carboxyl and coupling it to the growing chain's free N-terminal amine — the reverse of ribosomal, biological N-to-C synthesis. This makes explicit terminus bookkeeping essential: chemists must track which end is anchored and which is growing, and the final released, deprotected peptide is still reported using the same universal N→C reading convention regardless of the direction it was physically assembled on the resin, because "how you name it" and "which end you build first synthetically" are related but logically separate questions. In mass-spectrometry-based proteomics (Peptide Sequencing Strategies), tandem MS fragmentation of peptide ions produces characteristic b-ions (fragments retaining the N-terminus) and y-ions (fragments retaining the C-terminus); correctly assigning which ion series is which, and hence reconstructing sequence, depends entirely on the same N→C directional bookkeeping established here — a b₃ ion, for instance, is by definition the N-terminal fragment containing residues 1–3, only meaningful once "residue 1" is unambiguously anchored to the N-terminus. Pharmaceutical peptide naming (e.g., insulin's A-chain and B-chain sequences, glucagon-like peptide-1 analogs such as semaglutide) likewise reports sequence, residue substitutions, and chain termini using this same universal convention, making it possible for a chemist, a clinician, and a database curator anywhere in the world to refer to "residue 8" of a given peptide and mean the identical atom.
Ask the tutor: If a cyclic peptide has no free N- or C-terminus, how do biochemists decide which residue to call "residue 1" when reporting its structure?
The physical picture — thorough prose
Consider a tripeptide made from alanine, glycine, and lysine, joined so that alanine's carboxyl condenses with glycine's amino group, and glycine's carboxyl condenses with lysine's amino group. After two dehydration condensations forming two peptide (amide) bonds, the molecule has a backbone running: free α-amino group of alanine → Cα(Ala) → C(=O)–NH → Cα(Gly) → C(=O)–NH → Cα(Lys) → free α-carboxyl group of lysine. Only the alanine end retains a free, protonatable α-amino group; only the lysine end retains a free, ionizable α-carboxyl group. Every internal amino and carboxyl group has been consumed in amide bond formation (except lysine's side-chain ε-amino group, which remains free but is not part of the backbone). This is the essential physical fact: peptide bond formation is directional condensation. The reaction always consumes the carboxyl of the "upstream" residue and the amino group of the "downstream" residue, releasing water:
Once you link many residues this way, only the two ends of the chain remain unreacted. No matter how long the chain, there are always exactly two termini, and they are chemically distinguishable — an amino terminus and a carboxyl terminus — because amide bond formation is asymmetric at each step (it always uses up one carboxyl and one amino group per bond, never two of the same kind at an internal junction). Biology exploits and enforces this asymmetry through the ribosome. During translation, the growing peptide chain is held on a tRNA as a peptidyl-tRNA ester at its C-terminal carboxyl, and the incoming aminoacyl-tRNA presents a free α-amino group that attacks the ester carbonyl of the peptidyl-tRNA in the peptidyl transferase center. This nucleophilic acyl substitution transfers the growing chain onto the new amino acid's amino group, extending the chain by one residue at the carboxyl end while leaving a fresh α-amino group exposed at the far, N-terminal end (which is normally the first residue incorporated, and stays fixed while new residues are added at the other end). The chain therefore grows unidirectionally: N-terminus is established first (from the initiator methionine or formyl-methionine in bacteria) and stays fixed, while the C-terminus is the growing, reactive end until translation terminates. This is why sequence convention (N→C) is not an arbitrary human choice layered onto a symmetric object — it mirrors the actual chemical order of synthesis in the cell.
The two peptide bonds in this tripeptide are highlighted in red; each one is formed by the reaction of an α-carboxyl with the next residue's α-amino group. Two bonds link three residues, and only two termini remain free — one amino, one carboxyl — no matter which residues are chosen.
Numbering always starts at 1 at the N-terminal residue and increases toward the C-terminus. This is why disease mutations, active-site residues, and post-translational modification sites are always cited with a residue number that is meaningless unless the numbering direction is agreed — and it always is, by the same N→C rule.
The core ideas — governing relationships
The "equations" of peptide nomenclature are really structural bookkeeping rules, but they are exact and must be applied consistently. Three relationships govern everything in this article.
1. Residue count and peptide bond count. For a linear, unbranched peptide of amino acid residues joined by ordinary peptide bonds (no cyclization, no branching via side chains):
where:
- = number of amino acid residues in the chain,
- each peptide bond consumes one water molecule upon formation (condensation).
Reading: a chain of residues always has exactly one fewer peptide bond than residues, because bond formation links residue to residue and there is no bond "before" residue 1 or "after" residue .
2. Molecular mass of a peptide from constituent amino acid masses. Because each peptide bond formation releases one water (mass 18.02 g/mol):
where:
- = molar mass of free amino acid (as the neutral zwitterion, standard tabulated value),
- = number of residues,
- g/mol = mass of one water molecule lost per peptide bond.
Reading: you cannot simply add up free amino acid masses to get a peptide's mass — you must subtract one water per bond formed, and the number of bonds is fixed by relationship 1.
3. Residue index as a function of position from the N-terminus. If residue is positions from the N-terminal amino acid (the N-terminal residue itself being ):
where:
- = residue number (always counted from the N-terminal end by convention),
- = total residue count.
Reading: this is a definitional convention, not a physical law, but it is applied so universally (UniProt, PDB, clinical mutation nomenclature, IUPAC) that violating it makes a sequence uninterpretable to anyone else in the field.
Goal. Show rigorously why a peptide's mass equals the sum of free amino acid masses minus waters, and confirm the formula against a concrete asymmetric tripeptide.
Step 1 — Write the condensation reaction explicitly. Peptide bond formation between two amino acids, generically:
Mass balance requires
This is exact for a single bond: one condensation, one water lost, two free amino acids become a dipeptide.
Step 2 — Extend to a third residue. Adding AA₃ to the dipeptide via a second condensation:
Substituting the Step 1 result:
Each new residue added contributes one more subtracted water, confirming that after condensations joining residues, exactly waters have been lost.
Step 3 — General induction. Assume the formula holds for a chain of residues:
Adding residue by one more condensation:
which matches the general formula with , confirming it by induction for any chain length.
Step 4 — Numerical check with an asymmetric tripeptide, Ala-Gly-Lys. Free amino acid molar masses (zwitterionic form, standard values): alanine g/mol, glycine g/mol, lysine g/mol. Sum:
Subtract waters, g/mol:
This matches the tabulated monoisotopic/average mass for the tripeptide H-Ala-Gly-Lys-OH (average mass ≈ 274.32 g/mol, small rounding from tabulated constants), confirming the formula on a genuinely asymmetric, non-round three-residue example.
Limiting case. For (a single free amino acid, no peptide bond at all), the formula gives , correctly reducing to the free amino acid's own mass with zero waters subtracted — consistent with relationship 1, which gives zero peptide bonds when .
Go deeper · Derivation B · 3 minWhy N→C is the only self-consistent numbering and naming direction
Goal. Show that reading/numbering a peptide C→N instead of N→C is not merely "the other convention" but produces genuine ambiguity and inconsistency with the chemistry of synthesis, using an explicit non-palindromic example.
Step 1 — Establish the physical asymmetry. Take a real dipeptide formed from serine and phenylalanine. Serine's α-carboxyl condenses with phenylalanine's α-amino group:
The product has serine's free α-amino group at one end and phenylalanine's free α-carboxyl group at the other. This molecule, "Ser-Phe," is chemically and structurally distinct from "Phe-Ser," the alternative dipeptide formed by condensing phenylalanine's carboxyl with serine's amino group. They are constitutional isomers with different NMR spectra, different chromatographic behavior, and (if either has biological activity) potentially completely different bioactivity.
Step 2 — Suppose we adopted a C→N reading/writing convention instead. Under a hypothetical C→N rule, the same physical molecule (serine's amine free, phenylalanine's carboxyl free) would be written "Phe-Ser" — because we would now list the C-terminal residue first. This is self-consistent in isolation, but it collides catastrophically with two external facts that are not conventions but physical law: (i) Ribosomes always synthesize N-to-C; the codon table, the mRNA reading frame, and the direction of translation are fixed by the chemistry of the peptidyl transferase center (nucleophilic attack of the incoming amino group on the peptidyl-tRNA ester). A C→N naming convention would then have gene sequences read 5′→3′ correspond to protein sequences read backward relative to synthesis order — every textbook diagram of translation, every codon-to-residue correspondence table, would need inversion relative to naming. (ii) Enzymatic naming (aminopeptidases cleave from the N-terminus; carboxypeptidases from the C-terminus) already presupposes a universally agreed "N-terminus" label independent of which way you choose to write the string. Changing the writing convention doesn't change which end is chemically the amino end — but it would make "residue 1" refer to different physical atoms depending on which lab you're in, breaking mutation nomenclature (e.g., a literature statement "residue 12 is glycine in the wild type" becomes meaningless without also specifying reading direction).
Step 3 — Show the ambiguity concretely with numbering. Consider the hypothetical mutation "residue 2 of Ser-Phe is mutated to alanine." Under N→C numbering (the actual convention), residue 2 is phenylalanine, so the mutant is Ser-Ala. Under a C→N numbering scheme applied to the same molecule, residue 2 would instead be serine, and "residue 2 mutated to alanine" would mean Ala-Phe — a completely different molecule. The mutation label "residue 2 → Ala" is only unambiguous once a numbering direction is fixed; because biology's actual synthesis machinery fixes N→C physically, adopting N→C as the nomenclature direction is the only choice that keeps naming, numbering, and biosynthesis mutually consistent.
Step 4 — Generalize. For any peptide of residues, reversing the naming direction is equivalent to relabeling residue as residue . This relabeling is a well-defined bijection, so it does not introduce mathematical ambiguity by itself — but it desynchronizes nomenclature from the physical direction of ribosomal synthesis and from every existing sequence database, and for any peptide that is not palindromic (i.e., whose sequence is not equal to its own reverse), it also describes a chemically different molecule if the directionality of bond formation is also reversed rather than merely the labeling of a fixed molecule. This is the deeper reason the convention is fixed once and never renegotiated per-paper: consistency with (a) ribosomal chemistry, (b) every existing database, and (c) unambiguous mutation/residue reference all simultaneously require N→C.
Limiting case. For a palindromic dipeptide such as Gly-Gly, reversing the direction of reading produces the identical string ("Gly-Gly" read backward is "Gly-Gly"), so no ambiguity arises — a useful check that the argument in Step 3 is really about non-symmetric sequences, exactly the kind of case this derivation deliberately used (Ser-Phe, not Gly-Gly) to expose the effect.
Worked examples
Example 1 (Foundational): Writing and numbering a pentapeptide from a description. A peptide hormone fragment is described as: "glycine joined to phenylalanine joined to alanine joined to valine, with the final residue being aspartate, synthesized in that biological order." Write its three-letter sequence, one-letter sequence, and number each residue. Step 1. "Synthesized in that biological order" tells us the N-to-C order directly, since ribosomal synthesis proceeds N→C and residues are added at the C-terminal end as they are described in order: Gly (first made, becomes N-terminus) → Phe → Ala → Val → Asp (last made, becomes C-terminus). Step 2. Three-letter sequence, N→C:
The "H-" and "-OH" prefixes/suffixes explicitly denote the free α-amino hydrogen at the N-terminus and free α-carboxyl hydroxyl at the C-terminus — standard peptide-chemistry notation. Step 3. One-letter sequence, same direction:
Step 4. Residue numbering (N-terminus = 1):
| Position | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| Residue | Gly | Phe | Ala | Val | Asp |
| One-letter | G | F | A | V | D |
Step 5. Check with the bond-count relationship: residues implies peptide bonds, consistent with four condensation steps needed to link five residues into one unbranched chain.
Example 2 (Applied): Computing the mass of a signaling peptide and confirming against a mass spectrum. Met-enkephalin is an endogenous opioid pentapeptide with sequence Tyr-Gly-Gly-Phe-Met (N→C). A mass spectrometrist observes a singly protonated ion at (average mass, ). Confirm this is consistent with the proposed sequence. Step 1. Look up average free amino acid molar masses: Tyr , Gly , Gly , Phe , Met g/mol. Step 2. Sum:
Step 3. Subtract waters, g/mol:
Step 4. The observed ion should be , matching the reported to within instrument rounding — confirming both the proposed sequence's composition and, implicitly, that the peptide bond count used () is correct for a linear pentapeptide (no branching, no cyclization, consistent with enkephalin's known linear structure). Step 5. Note that this mass calculation alone cannot distinguish Tyr-Gly-Gly-Phe-Met from any permutation of the same five residues (e.g., Gly-Tyr-Gly-Phe-Met) — mass is order-independent. Establishing the actual N→C order requires sequencing methods (Edman degradation or tandem MS fragmentation), which is precisely why Peptide Sequencing Strategies must exist as a separate, non-trivial technique: composition alone never fixes sequence.
Example 3 (Exam/competition level): Reconstructing a full IUPAC-style substitutive name and resolving an ambiguous numbering claim. A student is given the tripeptide H-Val-Cys-Gly-OH and asked to (a) write its formal name using the acyl-substituent naming convention, and (b) evaluate the claim "residue 2 in this peptide is glycine" for correctness. Step 1 — Formal peptide naming rule. In IUPAC/biochemical peptide nomenclature, every residue except the C-terminal one is named as an acyl group (replacing the "-ine"/"-ic acid" ending with "-yl," denoting that its carboxyl has formed an amide bond), and only the final, C-terminal residue keeps its full, unmodified amino acid name (retaining its free carboxylic acid). Names are concatenated N-to-C. Step 2 — Apply to each residue. Valine (N-terminal, first residue) becomes "valyl" (its α-carboxyl is used in amide bond formation to Cys). Cysteine (internal residue) becomes "cysteinyl" (its α-carboxyl is likewise consumed, bonding to Gly's amino group). Glycine (C-terminal, last residue) remains simply "glycine," because its α-carboxyl is free. Step 3 — Concatenate.
This is the full substitutive name of H-Val-Cys-Gly-OH, read (as always) N-terminus first. Step 4 — Evaluate the numbering claim. By the universal N→C numbering convention, residue 1 = Val, residue 2 = Cys, residue 3 = Gly. The claim "residue 2 is glycine" is false — residue 2 is cysteine; glycine is residue 3 (the C-terminal residue). This is exactly the kind of numbering error the earlier derivation (Derivation 2, Step 3) showed produces real ambiguity: whoever made the claim may have implicitly counted from the C-terminus (making glycine "position 2 from the end"), illustrating why residue numbers must always be explicitly anchored to the N-terminus to be meaningful in any exam, paper, or clinical report. Step 5 — Sanity check via mass formula. Val (), Cys (), Gly () sum to g/mol; subtract ; g/mol for valylcysteinylglycine — consistent with tabulated values for H-Val-Cys-Gly-OH, confirming the sequence assignment used is self-consistent with the naming derived in Steps 1–3.
Limiting cases, scope & common traps
| Situation | What happens to nomenclature | Why |
|---|---|---|
| Dipeptide () | Only one peptide bond; N-terminal residue named as "-yl," C-terminal residue keeps full name (e.g., alanylglycine) | Formula bond; naming rule still applies with just one acyl prefix |
| Single free amino acid () | No peptide bond, no termini distinction beyond the amino acid's own α-amino/α-carboxyl groups; mass formula reduces to | Zero bonds formed; not a "peptide" in the directional sense at all |
| Cyclic peptide (head-to-tail cyclization) | No free N- or C-terminus exists; standard N→C numbering convention breaks down and must be replaced by an arbitrary starting-residue convention stated explicitly by the authors | The defining physical asymmetry (one free amine, one free acid) is destroyed by cyclization |
| Palindromic sequence (e.g., Gly-Ala-Gly) | Sequence read backward gives the same string, but the molecule is still directional; N-terminal Gly and C-terminal Gly are chemically distinct despite identical residue identity | Sequence string symmetry does not imply chemical symmetry — N-terminal Gly has a free α-NH₃⁺, C-terminal Gly has a free α-COO⁻ |
| Branched/side-chain-linked peptides (e.g., isopeptide bonds via Lys side chains, as in ubiquitin conjugation) | Simple linear numbering and the bond-count rule no longer directly apply; branch points must be specified separately | Peptide bonds can form through side-chain amines (Lys ε-NH₂) or carboxyls (Asp/Glu side chains), adding topology beyond a simple chain |
| One-letter vs. three-letter code mixing | Never mix codes within one sequence string (e.g., "Ala-G-Lys" is nonstandard); pick one alphabet and use it consistently | Mixing breaks machine-readability and human parsing conventions used by every database (UniProt, PDB, NCBI) |
The chemist behind it
Peptide sequence convention as we use it today traces most directly to Emil Fischer, the German organic chemist whose systematic synthesis and characterization of di- and tripeptides in the early 1900s established both the chemical reality of the amide (peptide) linkage between amino acids and the practical need for a consistent way to describe which amino acid came "first." Fischer synthesized glycylglycine and related dipeptides by controlled condensation reactions, definitively showing that amino acids link through carboxyl-to-amino condensation rather than through some other bonding pattern that had been debated (such as diketopiperazine-type ring structures being the only linkage). His painstaking, atom-by-atom synthetic work — for which he had already won the 1902 Nobel Prize in Chemistry for sugar and purine synthesis — gave biochemistry both the term "peptide" and the recognition that these chains have a built-in chemical asymmetry, since his controlled syntheses necessarily specified which amino acid's carboxyl reacted with which amino acid's amine. The modern formalization of nomenclature — three-letter codes standardized in the 1960s, one-letter codes introduced by Margaret Oakley Dayhoff for compact representation in her Atlas of Protein Sequence and Structure, and the IUPAC-IUBMB joint recommendations fixing N→C as the writing and numbering direction — came later, once enough protein sequences existed that a compact, unambiguous, database-friendly alphabet became a practical necessity rather than a convenience. Dayhoff's one-letter code, in particular, was explicitly engineered for computational sequence storage and comparison at a time when data storage was scarce, and her choices (such as using single letters that are mnemonic where possible — G for glycine, A for alanine — and arbitrary where necessary, since the alphabet has only 26 letters for 20 amino acids plus ambiguity codes) remain the universal standard in every sequence database today.
Origins · 1 minEmil Fischer and how this was discovered
Fischer's systematic synthesis of dipeptides and tripeptides via carboxyl-amine condensation proved experimentally that amino acids link through directional amide bonds, providing the chemical basis on which all later sequence-naming conventions (N-terminus first, C-terminus last) were built.
Why does the peptide bond force a chain to have only two distinguishable ends, no matter how long it is?
Each peptide bond forms by condensing one residue's α-carboxyl group with the next residue's α-amino group, releasing water. This reaction is asymmetric at every step: it always consumes exactly one carboxyl and one amino group per bond, never two amino or two carboxyl groups simultaneously. When you chain many residues this way, every internal residue's α-amino and α-carboxyl groups get consumed in forming bonds to its neighbors on both sides, leaving only the very first residue's amino group and the very last residue's carboxyl group unreacted. This is true regardless of chain length — a 500-residue protein still has exactly one free N-terminal amine and one free C-terminal carboxyl (barring post-translational blocking modifications), because the underlying bond-forming chemistry never changes.
Is the N-to-C writing convention the same as the direction ribosomes actually build proteins?
Yes, and this is not a coincidence — it's the historical reason the convention was chosen. Ribosomes always synthesize proteins starting from the N-terminus (beginning with the initiator methionine, or formylmethionine in bacteria) and extend the chain by adding new residues to the C-terminal end via the peptidyl transferase center, until a stop codon triggers release. Because sequencing methods historically read out protein structure in this same biological order, and because it matches the physical order of synthesis, writing sequences N-to-C keeps nomenclature synchronized with biology rather than working against it.
Do solid-phase peptide synthesis chemists build peptides in the same direction ribosomes do?
No — this is a genuinely important asymmetry to keep straight. Standard solid-phase peptide synthesis (Fmoc or Boc chemistry) anchors the first, C-terminal amino acid to a solid resin through its carboxyl group, then couples subsequent amino acids by activating each new residue's carboxyl and reacting it with the growing chain's free N-terminal amine — building the chain C-to-N, in the opposite physical order from ribosomal synthesis. Despite being built in reverse, the finished, cleaved peptide is still reported using the same universal N→C sequence convention, because naming convention describes the final molecule's structure, not the order of chemical steps used to construct it.
How do the one-letter and three-letter amino acid codes relate to each other, and when is each used?
Both alphabets represent the same 20 standard amino acids and are always read in the same N-to-C order; they differ only in compactness. Three-letter codes (Ala, Gly, Lys, etc.) are more readable for humans, especially in prose, tables, and when discussing individual residues, and they are used almost universally in textbooks and structural biology papers. One-letter codes (A, G, K, etc.), introduced for computational compactness, are the standard for long sequence alignments, database entries (UniProt, GenBank), and any context where sequences of hundreds of residues need to be displayed or processed efficiently; a few one-letter codes are non-mnemonic (e.g., W for tryptophan, since T was already taken by threonine) and must simply be memorized.
Why can't peptide mass alone determine the sequence order of residues?
Molecular mass is an additive property that depends only on which amino acids are present and how many peptide bonds have formed — it carries no information about the order in which those residues are connected. Two peptides with identical amino acid composition but different sequence order (e.g., Gly-Tyr-Ala versus Tyr-Gly-Ala) have exactly the same molecular mass, because the same atoms are present and the same number of water molecules were lost regardless of connection order. Determining actual sequence order requires methods that probe the chain stepwise from one end, such as Edman degradation (which sequentially removes and identifies N-terminal residues) or tandem mass spectrometry fragmentation, which is why sequencing is a distinct technical problem from simply measuring composition or total mass.
How is residue numbering affected when a protein has a cleaved signal peptide or propeptide?
This is a genuine practical complication. Many proteins are synthesized with an N-terminal signal peptide (directing secretion or membrane insertion) or a propeptide region that is proteolytically removed to generate the mature, functional protein. Databases and papers must specify whether residue numbers refer to the precursor sequence (including the signal/propeptide, numbering from the very first translated methionine) or the mature sequence (numbering from the first residue of the processed, functional protein) — the same physical residue can have two different numbers depending on which convention is used. Always check which numbering scheme a source uses before comparing residue numbers across papers or databases.
What happens to N- and C-terminal nomenclature for a cyclic peptide?
Head-to-tail cyclic peptides (where the C-terminal carboxyl condenses with the N-terminal amine to close the ring, as in some antimicrobial and immunosuppressant peptides like cyclosporine) have no free α-amino or α-carboxyl group at all — every residue's backbone amino and carboxyl groups are consumed in ring-forming amide bonds. Because the defining physical asymmetry (one free amine, one free acid) that grounds the N→C convention no longer exists, there is no chemically privileged starting point for numbering; authors must simply state an arbitrary starting residue and direction explicitly, and different papers describing the same cyclic peptide may use different starting points, requiring extra care when comparing residue numbers between sources.